In Continuation of Postal Ballot Notice dated 09th July 2026 , Submitting Corrigendum as integral part to the Said Notice.

To To Date: July 23, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Corrigendum to the Postal Ballot Notice dated 09th July 2026 Dear Sir/Madam, In continuation to our intimation dated 09th July, 2026, we are submitting herewith the corrigendum to the Notice of Postal Ballot. A copy of the detailed Corrigendum is enclosed herewith. Copy of the said corrigendum to the Notice of Postal Ballot is also uploaded on the website of the Company www.balpharma.com The corrigendum shall form an integral part to the Notice of Postal Ballot and should be read in conjunction with the aforesaid Notice of Postal Ballot. You are requested to kindly take the same on your records Thanking You. For Bal Pharma Ltd Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681 Enclosure: As above BAL PHARMA LIMITED CIN: L85110KA1987PLC008368 Regd Office: 21 & 22, Bommasandra Industrial Area, Bengaluru- 560099 Phone: 41379500, Fax: 22354057, E-mail: secretarial@balpharma.com, Website: www.balpharma.com CORRIGENDUM TO THE POSTAL BALLOT NOTICE DATED 9TH JULY 2026 This Corrigendum ("Corrigendum") is being issued in continuation of and in connection with the Postal Ballot Notice dated 9th July 2026 ("Original Notice") issued by Bal Pharma Limited ("Company") to the Members of the Company, seeking their approval by way of Special Resolution through remote e-Voting for the proposed preferential issue of up to 10,00,000 (Ten Lakh) convertible warrants ("Warrants") to Mr. Shailesh Siroya, Promoter of the Company ("Proposed Allottee"). The remote e-Voting process in respect of the Original Notice commenced on Friday, 10 July 2026 at 09:00 A.M. (IST) and shall conclude on Saturday, 08 August 2026 at 05:00 P.M. (IST). The Company had filed applications with BSE Limited ("BSE") and National Stock Exchange of India Limited ("Stock Exchanges") for obtaining the requisite in-principle approvals in respect of the proposed preferential issue, in accordance with Regulation 28(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"). Pursuant thereto, the Stock Exchanges, while examining the proposed preferential issue in accordance with the applicable provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"), have sought certain clarifications and additional information from the Company. Accordingly, based on the clarifications and additional information furnished / proposed to be furnished to the Stock Exchanges and the applicable provisions of the SEBI ICDR Regulations, the Company is issuing this Corrigendum to the Members. This Corrigendum shall form an integral part of the Original Notice and the Explanatory Statement annexed thereto and shall be read in conjunction with the Original Notice. The Members are requested to read this Corrigendum carefully along with the Original Notice. Except to the extent expressly modified, amended, supplemented or clarified by this Corrigendum, all other terms, conditions, disclosures and contents of the Original Notice, including the Special Resolution proposed thereunder, shall remain unchanged and shall continue to be valid. Accordingly, the following modifications / amendments shall be read as forming part of the Original Notice: 1. REVISION IN THE ISSUE PRICE OF WARRANTS The Members are hereby informed that the issue price of the Warrants proposed to be issued on preferential basis to the Proposed Allottee is revised from ₹81/- (Rupees Eighty- One only) per Warrant to ₹84/- (Rupees Eighty-Four only) per Warrant, including a premium of ₹74/- (Rupees Seventy-Four only) per Warrant. Accordingly, the aggregate consideration for the proposed issue of 10,00,000 (Ten Lakh) Warrants shall stand revised from ₹8,10,00,000/- (Rupees Eight Crore Ten Lakh only) to ₹8,40,00,000/- (Rupees Eight Crore Forty Lakh only). The proposed issue shall continue to comprise 10,00,000 (Ten Lakh) Warrants, each Warrant being convertible into 1 (one) Equity Share of the Company having a face value of ₹10/- each, subject to the terms and conditions set out in the Original Notice, as modified by this Corrigendum. Pricing of the Warrants The Equity Shares of the Company are listed on NSE and BSE and are frequently traded within the meaning of Regulation 164(5) of the SEBI ICDR Regulations. Since NSE has higher trading volumes for the relevant period, NSE has been considered for determining the floor price in accordance with the applicable provisions of the SEBI ICDR Regulations. As the proposed preferential issue is expected to result in the allotment of Equity Shares pursuant to conversion of Warrants exceeding 5% of the post-issue fully diluted share capital of the Company, the provisions of Regulation 166A of the SEBI ICDR Regulations are applicable. Accordingly, the Company has obtained a valuation report dated 22 July 2026 from Mr. CA S. Bhaskar, Independent Registered Valuer, Registration No. IBBI/RV/06/2019/12116, covering the determination of fair value under the following approaches: Particulars Value per share Market Approach Rs. 83.869/- Income & cost Approach Rs. 82.65/- Asset Approach Rs. 45.76/- Accordingly, the highest value determined under the applicable valuation approaches is ₹83.869/- per Equity Share. Further, in accordance with the applicable provisions of Regulations 164 and 166A of the SEBI ICDR Regulations, the minimum price for the proposed preferential issue shall not be less than the higher of the applicable prices determined under the relevant provisions, including: 1. ₹83.869/- per Warrant, being the 90 trading days volume weighted average price of the Equity Shares of the Company quoted on the Stock Exchange preceding the Relevant Date; 2. ₹80.2778/- per Warrant, being the 10 trading days volume weighted average price of the Equity Shares of the Company quoted on the Stock Exchange preceding the Relevant Date; 3. ₹83.869/- per Warrant, being the price determined pursuant to the valuation report obtained from the Independent Registered Valuer in accordance with Regulation 166A of the SEBI ICDR Regulations; and 4. The price determined in accordance with the methodology prescribed under the Articles of Association of the Company, which is not applicable, as the Articles of Association of the Company do not contain any provision prescribing the methodology for determination of floor price / minimum price for preferential issue. Accordingly, the minimum issue price of the Warrants is ₹83.869/- per Warrant. The Company has decided to issue the Warrants at an issue price of ₹84/- (Rupees Eighty- Four only) per Warrant, which is higher than the applicable minimum price determined in accordance with the SEBI ICDR Regulations. Accordingly, the relevant portion of the Original Notice relating to the issue price and basis of arriving at the issue price shall stand modified to the aforesaid extent. The valuation report obtained from the Independent Registered Valuer shall be made available on the website of the Company at www.balpharma.com and shall be available for inspection by the Members in accordance with applicable law. 2. REVISION IN THE PAYMENT TERMS Consequent to the revision in the issue price of the Warrants from ₹81/- to ₹84/- per Warrant, the payment terms specified in the Original Notice shall stand modified as follows: The Warrant holder shall, on the date of allotment of Warrants, pay an amount equivalent to 25% of the total consideration, being ₹21/- (Rupees Twenty-One only) per Warrant. The Warrant holder(s) shall, before the date of conversion of the Warrants i [Showing first 8,000 characters — download PDF for full document]